Pfizer asks FDA to widen jab EUA to those aged 12-15

Friday, 09. April 2021 19:34

Pfizer Inc. has filed with the United States Food and Drug Administration (FDA) a request to expand the Emergency Use Authorization (EUA) it obtained in regard to its COVID-19 vaccine to adolescents aged between 12 and 15, the company unveiled on Friday.

Pfizer's statement added that the request was made based on "data from the pivotal Phase 3 trial in adolescents 12 to 15 years of age," which allegedly showcased the 100% efficacy against COVID within the age group with no severe side effects.

After the FDA request, the drugmaker looks to file for the same approval with other health regulators around the world, the statement concluded.

Related Links: Pfizer Inc.
Breaking the News / BU